---
title: "SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Clinical evidence"
description: "Formulary evidence on SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Clinical evidence. Covers SL1009-01, SL1009-02, Controlled clinical trial of dichloroacetate for congenital lactic acidosis in children, Dichloroacetate randomized controlled trial in MELAS, Long-term safety of dichloroacetate in congenital lactic acidosis, Chronic treatment of mitochondrial disease with dichloroacetate, and 10 further headings. 117 evidence topics quoted from 24 sources."
canonical: "https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/clinical-evidence"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 SL1009-01

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Pivotal evaluation of dichloroacetate

> “conduct a pivotal phase 3 trial of treatment with the investigational drug dichloroacetate (DCA)”

Source: [Stanford Health Care](https://stanfordhealthcare.org/trials/t/NCT02616484.html)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Multicenter trial initiation

> “In 2018, we began a multicenter phase 3 trial of DCA in PDCD”

Source: [Stacpoole and Dorsey (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10563500/)

<a id="topic-3.1.1.2-2"></a>

###### Participating centers

> “The study was conducted by nine academic health centers across the United States”

Source: [Stacpoole et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12450258/)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Randomized population and masking

> “randomized, placebo-controlled, double-blind trial of 34 children, aged 6 months through 17 years, with confirmed diagnosis of PDC Deficiency.”

Source: [Saol Therapeutics](https://saolrx.com/pipeline)

<a id="topic-3.1.1.3-2"></a>

###### Crossover and extension design

> “Thirty-four subjects, aged 6 months to 17 years, were randomized to DCA or placebo in a 9-month crossover study, followed by open label DCA of indefinite duration.”

Source: [Stacpoole et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12450258/)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Age, molecular diagnosis, and phenotype

> “Eligible children (6m-17y at entry) have a proven pathological mutation in any PDC component (except DLD) or in a pyruvate dehydrogenase phosphatase isoform, and a clinical phenotype consistent with PDCD.”

Source: [Stacpoole and Dorsey (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10563500/)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Treatment periods and washout

> “Each treatment arm lasts four months, separated by a one-month washout (w/o).”

Source: [Stacpoole et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6587967/)

<a id="topic-3.1.1.5-2"></a>

###### Genotype-directed investigational doses

> “subjects are genotyped to determine whether they are a “fast” (12.5mg/kg/12h) or “slow” (6.25mg/kg/12h) DCA metabolizer”

Source: [Stacpoole and Dorsey (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10563500/)

<a id="topic-3.1.1.5-3"></a>

###### Background treatment

> “Enrolled subjects continued their ketogenic diets and other supplements.”

Source: [Stacpoole et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12450258/)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using ObsRO Motor Function as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Daily parent or caregiver reporting

> “requires less than five minutes for a parent/caregiver to complete daily.”

Source: [Stacpoole et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6587967/)

<a id="topic-3.1.1.6.1-2"></a>

###### At-home function and symptom domains

> “at-home level of functionality”
> “motor; breathing; seizures; eating; fatigue; sleep; and general health.”

Source: [Stacpoole and Dorsey (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10563500/)

<a id="topic-3.1.1.6.1-3"></a>

###### Original scoring specification

> “The ObsRO scoring analysis includes 11 equally-weighted items reflecting at-home functionality.”
> “A negative slope indicates functional improvement”

Source: [Stacpoole et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6587967/)

<a id="topic-3.1.1.6.1-4"></a>

###### FDA assessment of plasma lactate as a surrogate

> “did not support the observed reduction in plasma lactate as a surrogate endpoint that predicts clinical benefit in PDCD.”

Source: [FDA complete response letter (2025)](https://download.open.fda.gov/crl/CRL_NDA218679_20250827.pdf)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Original evaluable sample-size target

> “We took advantage of the rapid pharmacodynamics effects of DCA to construct a double-blind, placebo-controlled, crossover trial of 24 evaluable children, aged 6 months through 17 years, with genetically proven PDCD.”

Source: [Stacpoole et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6587967/)

<a id="topic-3.1.1.7.1-2"></a>

###### Original recruitment goal

> “exceeding our original statistically based goal of 30 subjects.”

Source: [Stacpoole and Dorsey (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10563500/)

<a id="topic-3.1.1.7.1-3"></a>

###### Randomized sample

> “Thirty-four subjects”

Source: [Stacpoole et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12450258/)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Original analysis strategy and missing-data plan

> “an intent-to-treat strategy”
> “an appropriate imputation scheme for missing data”

Source: [Stacpoole et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6587967/)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Interim disposition at the conference reporting cutoff

> “23 patients have completed the double-blind period as of March 15, 2023, and 22 patients are now in the open-label phase.”

Source: [Stacpoole and Dorsey (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10563500/)

<a id="topic-3.1.1.8.1-2"></a>

###### Final randomized-period disposition by treatment sequence

No evidence found.

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Baseline demographics

> “34 children (8 males, 26 females), median age at entry 2 ½ yrs”

Source: [Stacpoole and Dorsey (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10563500/)

<a id="topic-3.1.1.8.2-2"></a>

###### Genetic diagnoses

> “33 patients have a mutation in PDHA1 and one patient has a mutation in PDHX.”

Source: [Stacpoole and Dorsey (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10563500/)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Original primary endpoint

> “The original primary efficacy endpoint, a novel Observer Reported Outcome (ObsRO) survey, was not met.”

Source: [Stacpoole et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12450258/)

<a id="topic-3.1.1.8.3-2"></a>

###### FDA primary-analysis treatment difference

> “treatment difference 0.29 [95% CI: -0.62, 1.21; p=0.52] favoring placebo arm”

Source: [FDA complete response letter (2025)](https://download.open.fda.gov/crl/CRL_NDA218679_20250827.pdf)

<a id="topic-3.1.1.8.3-3"></a>

###### Plasma lactate

> “DCA also significantly (p=0.006) decreased plasma lactate concentrations”

Source: [Stacpoole et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12450258/)

<a id="topic-3.1.1.8.3-4"></a>

###### Additional motor-function analysis in more seriously affected participants

> “Additional analysis suggested by the FDA showed a clinically meaningful, but not statistically significant (p=0.66), improvement in motor function among the most seriously affected subjects, based on ObsRO data.”

Source: [Stacpoole et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12450258/)

<a id="topic-3.1.1.8.3-5"></a>

###### Longer-duration treatment, including the open-label extension

> “Longer duration of therapy, including the open label extension (OLE), demonstrated a statistically significant improvement in motor function in the ITT population (p=0.002).”

Source: [Saol Therapeutics UMDF Mitochondrial Medicine 2025 poster announcement (2025)](https://saolrx.com/saol-therapeutics-announces-poster-presentation-at-the-umdf-mitochondrial-medicine-2025-conference/)

<a id="topic-3.1.1.8.3-6"></a>

###### FDA assessment of post hoc subgroup analyses

> “The proposed post hoc analyses for the subgroup of subjects with Period 1 baseline ObsRO motor score ≥ 8 were deemed inappropriate to determine the presence of a DCA treatment effect.”

Source: [FDA complete response letter (2025)](https://download.open.fda.gov/crl/CRL_NDA218679_20250827.pdf)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Most commonly reported adverse reaction occurring in more than 5% of participants

> “gastrointestinal disorders (n=2, 5.9%).”

Source: [Saol Therapeutics UMDF Mitochondrial Medicine 2025 poster announcement (2025)](https://saolrx.com/saol-therapeutics-announces-poster-presentation-at-the-umdf-mitochondrial-medicine-2025-conference/)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

The trial enrolled 34 participants and did not meet its original primary endpoint. The FDA did not accept the proposed post hoc subgroup analyses or plasma lactate reduction as evidence establishing clinical benefit. The reported p=0.002 motor-function finding included longer treatment and the open-label extension, rather than demonstrating success on the randomized primary comparison. The p=0.66 analysis in more seriously affected participants was also not statistically significant. The report provides an interim disposition update, but not final participant disposition by randomized sequence. The original design publication describes an intention-to-treat strategy and planned imputation, but is not a complete account of the final analysis implementation.

Source: [Saol Therapeutics](https://saolrx.com/pipeline); [FDA complete response letter (2025)](https://download.open.fda.gov/crl/CRL_NDA218679_20250827.pdf); [Saol Therapeutics UMDF Mitochondrial Medicine 2025 poster announcement (2025)](https://saolrx.com/saol-therapeutics-announces-poster-presentation-at-the-umdf-mitochondrial-medicine-2025-conference/); [Stacpoole et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12450258/); [Stacpoole and Dorsey (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10563500/); [Stacpoole et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6587967/)

<a id="topic-3.1.1.9-2"></a>

###### Manuscript listing status

> “Phase 3 Trial of Sodium Dichloroacetate for Pyruvate Dehydrogenase Complex Deficiency (PDCD) in Children. JCI Insight In Revision 2026.”

Source: [University of Pennsylvania faculty bibliography](https://www.med.upenn.edu/apps/faculty/index.php/g275/p8141835)

<a id="heading-3.1.2"></a>

#### 3.1.2 SL1009-02

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Survival comparison

> “SL1009-02 compared survival of subjects who received DCA in SL1009-01 to an external control derived from a published 2012 natural history study of PDCD by DeBrosse et al.”

Source: [FDA complete response letter (2025)](https://download.open.fda.gov/crl/CRL_NDA218679_20250827.pdf)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Noncontemporaneous cohorts

> “temporal separation (average 18 years)”

Source: [FDA complete response letter (2025)](https://download.open.fda.gov/crl/CRL_NDA218679_20250827.pdf)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

Additional sources: [FDA complete response letter (2025)](https://download.open.fda.gov/crl/CRL_NDA218679_20250827.pdf)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

Additional sources: [FDA complete response letter (2025)](https://download.open.fda.gov/crl/CRL_NDA218679_20250827.pdf)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Survival as the Primary Endpoint

Not applicable.

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

No evidence found.

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### FDA assessment of imputation in the external-control analysis

> “imputation protocol was inconsistently applied introducing bias against the external control group.”

Source: [FDA complete response letter (2025)](https://download.open.fda.gov/crl/CRL_NDA218679_20250827.pdf)

<a id="topic-3.1.2.7.2-2"></a>

###### Additional analyses described in the subsequent resubmission announcement

> “additional survival analyses to support the application”
> “Saol conducted further analyses of existing data”

Source: [Saol Therapeutics NDA resubmission announcement (2026)](https://saolrx.com/saol-therapeutics-resubmits-the-new-drug-application-for-sl1009-dca-for-the-treatment-of-pyruvate-dehydrogenase-complex-deficiency-pdcd-an-ultra-rare-disease/)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### FDA assessment of severity imbalance

> “structural brain abnormalities most commonly associated with severe disease favored the DCA-treated group.”

Source: [FDA complete response letter (2025)](https://download.open.fda.gov/crl/CRL_NDA218679_20250827.pdf)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Sponsor-reported survival result

> “DCA treatment improved survival (p=0.027) compared to appropriately matched controls.”

Source: [Saol Therapeutics UMDF Mitochondrial Medicine 2025 poster announcement (2025)](https://saolrx.com/saol-therapeutics-announces-poster-presentation-at-the-umdf-mitochondrial-medicine-2025-conference/)

<a id="topic-3.1.2.8.3-2"></a>

###### FDA assessment of the proposed comparison

> “cannot be used to assess the treatment effect of DCA on survival”

Source: [FDA complete response letter (2025)](https://download.open.fda.gov/crl/CRL_NDA218679_20250827.pdf)

<a id="topic-3.1.2.8.3-3"></a>

###### Quantitative results of the additional resubmission analyses

No evidence found.

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

No evidence found.

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

This comparison reused the SL1009-01 treatment cohort and was not an independent randomized trial. The FDA identified inconsistent imputation, disease-severity imbalance, and an average temporal separation of 18 years between cohorts in its 2025 assessment. These limitations prevent interpreting the sponsor-reported p=0.027 as an established causal survival benefit. The subsequent resubmission announcement describes further analyses, including FDA-requested survival analyses, but this report contains no quantitative results from those additional analyses.

Source: [FDA complete response letter (2025)](https://download.open.fda.gov/crl/CRL_NDA218679_20250827.pdf); [Saol Therapeutics UMDF Mitochondrial Medicine 2025 poster announcement (2025)](https://saolrx.com/saol-therapeutics-announces-poster-presentation-at-the-umdf-mitochondrial-medicine-2025-conference/); [Saol Therapeutics NDA resubmission announcement (2026)](https://saolrx.com/saol-therapeutics-resubmits-the-new-drug-application-for-sl1009-dca-for-the-treatment-of-pyruvate-dehydrogenase-complex-deficiency-pdcd-an-ultra-rare-disease/)

<a id="heading-3.1.3"></a>

#### 3.1.3 Controlled clinical trial of dichloroacetate for congenital lactic acidosis in children

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Therapeutic evaluation

> “treating patients with congenital lactic acidosis”

Source: [Stacpoole et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16651305/)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Long-term follow-up endpoint

> “through May 2005”

Source: [Stacpoole et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3777225/)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Controlled phase

> “double-blind, randomized, control trial”

Source: [Stacpoole et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16651305/)

<a id="topic-3.1.3.3-2"></a>

###### Follow-up phase

> “an open-label study”

Source: [Stacpoole et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3777225/)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Investigational dose

> “12.5 mg/kg every 12 hours”

Source: [Stacpoole et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16651305/)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Global Assessment of Treatment Efficacy as a Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Composite clinical endpoint

> “Global Assessment of Treatment Efficacy”

Source: [Stacpoole et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16651305/)

<a id="topic-3.1.3.6.1-2"></a>

###### Endpoint validation and component weighting

No evidence found.

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Randomized-study enrollment

> “Forty-three patients”

Source: [Stacpoole et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16651305/)

<a id="topic-3.1.3.7.1-2"></a>

###### Long-term follow-up cohort

> “36 children”

Source: [Stacpoole et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3777225/)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Long-term analysis approach

> “Data were analyzed for each patient”

Source: [Stacpoole et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3777225/)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Long-term survival

> “Mean 3-year survival for all of the subjects was 79%.”

Source: [Stacpoole et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3777225/)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Pyruvate dehydrogenase deficiency subgroup

> “Eleven patients had pyruvate dehydrogenase deficiency”

Source: [Stacpoole et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16651305/)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Clinical efficacy

> “However, it did not improve neurologic or other measures of clinical outcome.”

Source: [Stacpoole et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16651305/)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Randomized-period tolerability

> “well tolerated”

Source: [Stacpoole et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16651305/)

<a id="topic-3.1.3.8.5-2"></a>

###### Long-term exposure and peripheral nerve findings

> “Subject exposure to dichloroacetate totaled 110.42 years.”
> “Conduction velocity decreased and distal latency increased in peroneal nerves.”

Source: [Stacpoole et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3777225/)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

Only 11 of the 43 enrolled participants had pyruvate dehydrogenase deficiency, limiting direct applicability of the overall trial result to PDCD. The reported clinical outcomes did not improve. The subsequent open-label follow-up involved 36 participants from the earlier controlled trial and therefore does not represent an independent randomized replication. Peripheral nerve changes during long-term exposure require consideration alongside the short-term tolerability finding.

Source: [Stacpoole et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16651305/); [Stacpoole et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3777225/)

<a id="heading-3.1.4"></a>

#### 3.1.4 Dichloroacetate randomized controlled trial in MELAS

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Efficacy of dichloroacetate in MELAS

> “To evaluate the efficacy of dichloroacetate (DCA) in the treatment of mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS).”
> “The authors hypothesized that chronic cerebral lactic acidosis exacerbates neuronal injury in MELAS and therefore, investigated DCA, a potent lactate-lowering agent, as potential treatment for MELAS.”

Source: [Kaufmann et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16476929/)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

No evidence found.

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Crossover design

> “3-year cross-over trial”

Source: [Kaufmann et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16476929/)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Disease and genotype

> “MELAS and the A3243G mutation”

Source: [Kaufmann et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16476929/)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Dichloroacetate dose

> “25 mg/kg/day”

Source: [Kaufmann et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16476929/)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Global Assessment of Treatment Efficacy as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Primary composite endpoint

> “Global Assessment of Treatment Efficacy (GATE)”

Source: [Kaufmann et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16476929/)

<a id="topic-3.1.4.6.1-2"></a>

###### Endpoint validation

No evidence found.

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Enrollment

> “30 patients”

Source: [Kaufmann et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16476929/)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Early termination

> “terminated early”

Source: [Kaufmann et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16476929/)

<a id="topic-3.1.4.8.1-2"></a>

###### Withdrawal of study medication by treatment arm

> “During the initial 24-month treatment period, 15 of 15 patients randomized to DCA were taken off study medication, compared to 4 of 15 patients randomized to placebo.”
> “The clinical trial was terminated early because of peripheral nerve toxicity.”

Source: [Kaufmann et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16476929/)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Between-group difference in mean composite score

> “not significantly different”

Source: [Kaufmann et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16476929/)

<a id="topic-3.1.4.8.3-2"></a>

###### Primary outcome and investigator conclusion on benefit

> “The mean GATE score was not significantly different between treatment arms.”
> “Under these experimental conditions, the authors were unable to detect any beneficial effect.”
> “The findings show that DCA-associated neuropathy overshadows the assessment of any potential benefit in MELAS.”

Source: [Kaufmann et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16476929/)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Discontinuations associated with neuropathy

> “Study medication was discontinued in 17 of 19 patients because of onset or worsening of peripheral neuropathy.”

Source: [Kaufmann et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16476929/)

<a id="topic-3.1.4.8.5-2"></a>

###### Dose-level conclusion on peripheral nerve toxicity

> “DCA at 25 mg/kg/day is associated with peripheral nerve toxicity resulting in a high rate of medication discontinuation and early study termination.”

Source: [Kaufmann et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16476929/)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

The trial enrolled 30 participants with MELAS and the A3243G mutation, not a PDCD population. It was terminated early, and the report documents peripheral neuropathy associated with 17 of 19 medication discontinuations. Its findings provide indirect safety information for chronic dichloroacetate exposure, but do not establish efficacy in PDCD.

Source: [Kaufmann et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16476929/)

<a id="heading-3.1.5"></a>

#### 3.1.5 Long-term safety of dichloroacetate in congenital lactic acidosis

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

Additional sources: [Abdelmalak et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3751427/)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

No evidence found.

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Study design

> “an open-label chronic safety study”

Source: [Abdelmalak et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3751427/)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Prior study participation

> “randomized controlled trials of DCA”

Source: [Abdelmalak et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3751427/)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Long-term dose and duration

> “oral dichloroacetate (DCA; 12.5 mg/kg/12 hours) for 9.7 to 16.5 years.”

Source: [Abdelmalak et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3751427/)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Blood Lactate as a Biochemical Outcome

No evidence found.

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Cohort size

> “8 patients”

Source: [Abdelmalak et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3751427/)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Pyruvate dehydrogenase complex deficiency subgroup

> “PDC; 3 patients”

Source: [Abdelmalak et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3751427/)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Blood lactate

> “DCA maintained normal blood lactate concentrations”

Source: [Abdelmalak et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3751427/)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Laboratory safety findings

> “Hematological, electrolyte, renal and hepatic status remained stable.”

Source: [Abdelmalak et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3751427/)

<a id="topic-3.1.5.8.5-2"></a>

###### Dose reduction or temporary discontinuation following nerve-conduction changes

> “in 3 patients”

Source: [Abdelmalak et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3751427/)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

This open-label safety cohort comprised 8 participants, including 3 with PDC deficiency, who had participated in earlier dichloroacetate trials. Treatment continued for 9.7 to 16.5 years. The selected long-term cohort and lack of a concurrent randomized comparison limit causal conclusions about efficacy or comparative safety. Stable laboratory measures did not exclude peripheral nerve findings that prompted dose reduction or temporary discontinuation in 3 participants.

Source: [Abdelmalak et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3751427/)

<a id="heading-3.1.6"></a>

#### 3.1.6 Chronic treatment of mitochondrial disease with dichloroacetate

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

Additional sources: [Barshop et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15464428/)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Reported treatment duration

> “3 weeks to 7 years”

Source: [Barshop et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15464428/)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Study format

> “an open-label format”

Source: [Barshop et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15464428/)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Daily dose range

> “11-50 mg/kg/day (34.6+/-13.1)”

Source: [Barshop et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15464428/)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Blood and Cerebrospinal Fluid Lactate as the Biochemical Outcomes

No evidence found.

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Cohort size and diagnostic heterogeneity

> “37 patients with various mitochondrial disorders”

Source: [Barshop et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15464428/)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Neurologic observations

> “A standardized neurologic inventory showed stabilization or improvement over one year.”

Source: [Barshop et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15464428/)

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

No evidence found.

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary

The study followed 37 participants with various mitochondrial disorders using an open-label format and variable treatment duration. These observations do not provide a randomized estimate of treatment effect in PDCD. Diagnostic heterogeneity and unblinded outcome assessment limit attribution of neurologic changes to dichloroacetate.

Source: [Barshop et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15464428/)

<a id="topic-3.1.6.9-2"></a>

###### Authors’ assessment of efficacy interpretation

> “it is difficult to determine the efficacy of DCA in this open-label study”

Source: [Barshop et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15464428/)

<a id="heading-3.1.7"></a>

#### 3.1.7 PDHX-related neonatal case report

<a id="heading-3.1.7.1"></a>

##### 3.1.7.1 Objective

Additional sources: [Starosta et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11578067/)

<a id="heading-3.1.7.2"></a>

##### 3.1.7.2 Location and Study Date

No evidence found.

<a id="heading-3.1.7.3"></a>

##### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

###### Case-report design

> “the case of a neonate”

Source: [Starosta et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11578067/)

<a id="heading-3.1.7.4"></a>

##### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

###### Molecular diagnosis

> “a homozygous deep intronic pathogenic variant”

Source: [Starosta et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11578067/)

<a id="heading-3.1.7.5"></a>

##### 3.1.7.5 Treatment

Additional sources: [Starosta et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11578067/)

<a id="heading-3.1.7.6"></a>

##### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

###### 3.1.7.6.1 Rationale for Using Blood Lactate as a Biochemical Outcome

Not applicable.

<a id="heading-3.1.7.7"></a>

##### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

###### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

###### Reported participant

> “a neonate”

Source: [Starosta et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11578067/)

<a id="heading-3.1.7.7.2"></a>

###### 3.1.7.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.7.8"></a>

##### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

###### 3.1.7.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.7.8.2"></a>

###### 3.1.7.8.2 Baseline Characteristics

<a id="topic-3.1.7.8.2-1"></a>

###### Neonatal presentation

> “severe lactic acidosis on the second day of life”

Source: [Starosta et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11578067/)

<a id="heading-3.1.7.8.3"></a>

###### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

###### Emergency investigational treatment and clinical response

> “The patient was started on dichloroacetate as an emergency investigational new drug (eIND), with a sharp decline in lactic acid levels and clinical stabilization.”

Source: [Starosta et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11578067/)

<a id="heading-3.1.7.8.4"></a>

###### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.7.8.5"></a>

###### 3.1.7.8.5 Safety Results

No evidence found.

<a id="heading-3.1.7.9"></a>

##### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

###### Summary

The evidence concerns one critically ill neonate with PDHX-related disease. The temporal association between emergency investigational treatment, reduced lactic acid, and stabilization is not a controlled estimate of efficacy. A single case cannot establish comparative benefit, durability, or the frequency of adverse effects.

Source: [Starosta et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11578067/)

<a id="heading-3.1.8"></a>

#### 3.1.8 PDCD case monitored by localized proton magnetic resonance spectroscopy

<a id="heading-3.1.8.1"></a>

##### 3.1.8.1 Objective

Additional sources: [Harada et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8656986/)

<a id="heading-3.1.8.2"></a>

##### 3.1.8.2 Location and Study Date

No evidence found.

<a id="heading-3.1.8.3"></a>

##### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

###### Case-report design

> “a case of pyruvate dehydrogenase deficiency”

Source: [Harada et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8656986/)

<a id="heading-3.1.8.4"></a>

##### 3.1.8.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.8.5"></a>

##### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

###### Treatment exposure

> “Dichloroacetate was administered”

Source: [Harada et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8656986/)

<a id="heading-3.1.8.6"></a>

##### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

###### 3.1.8.6.1 Rationale for Using Brain Lactate as a Biochemical Outcome

<a id="topic-3.1.8.6.1-1"></a>

###### Biochemical monitoring method

> “proton magnetic resonance spectroscopy (1H MRS)”

Source: [Harada et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8656986/)

<a id="topic-3.1.8.6.1-2"></a>

###### Validation as a predictor of clinical benefit

No evidence found.

<a id="heading-3.1.8.7"></a>

##### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

###### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

###### Reported participant

> “a case”

Source: [Harada et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8656986/)

<a id="heading-3.1.8.7.2"></a>

###### 3.1.8.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.8.8"></a>

##### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

###### 3.1.8.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.8.8.2"></a>

###### 3.1.8.8.2 Baseline Characteristics

<a id="topic-3.1.8.8.2-1"></a>

###### Clinical diagnosis and age at initial spectroscopy

> “West syndrome”
> “11 months”

Source: [Harada et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8656986/)

<a id="heading-3.1.8.8.3"></a>

###### 3.1.8.8.3 Efficacy Results

<a id="topic-3.1.8.8.3-1"></a>

###### Treatment withdrawal and recurrence

> “In accordance with the suspension of dichloroacetate, increase of lactate in the brain was detected and the convulsions reappeared.”

Source: [Harada et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8656986/)

<a id="heading-3.1.8.8.4"></a>

###### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.8.8.5"></a>

###### 3.1.8.8.5 Safety Results

No evidence found.

<a id="heading-3.1.8.9"></a>

##### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

###### Summary

This single-case observation links treatment withdrawal with increased brain lactate and recurrent convulsions. It lacks a randomized comparison and cannot establish a general treatment effect, a validated surrogate relationship, or the incidence of treatment-related harm.

Source: [Harada et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8656986/)

<a id="heading-3.1.9"></a>

#### 3.1.9 Partial pyruvate decarboxylase deficiency treated with dichloroacetate and benzoate

<a id="heading-3.1.9.1"></a>

##### 3.1.9.1 Objective

Additional sources: [McCormick et al. (1985)](https://pubmed.ncbi.nlm.nih.gov/4050860/)

<a id="heading-3.1.9.2"></a>

##### 3.1.9.2 Location and Study Date

No evidence found.

<a id="heading-3.1.9.3"></a>

##### 3.1.9.3 Study Design

<a id="topic-3.1.9.3-1"></a>

###### Clinical case

> “a neonate”

Source: [McCormick et al. (1985)](https://pubmed.ncbi.nlm.nih.gov/4050860/)

<a id="heading-3.1.9.4"></a>

##### 3.1.9.4 Eligibility Criteria

<a id="topic-3.1.9.4-1"></a>

###### Enzyme deficiency

> “partial deficiency”

Source: [McCormick et al. (1985)](https://pubmed.ncbi.nlm.nih.gov/4050860/)

<a id="heading-3.1.9.5"></a>

##### 3.1.9.5 Treatment

<a id="topic-3.1.9.5-1"></a>

###### Oral dichloroacetate dose

> “50 mg/kg dichloroacetate”

Source: [McCormick et al. (1985)](https://pubmed.ncbi.nlm.nih.gov/4050860/)

<a id="heading-3.1.9.6"></a>

##### 3.1.9.6 Study Outcomes

<a id="heading-3.1.9.6.1"></a>

###### 3.1.9.6.1 Rationale for Using Serum Lactate and Pyruvate as the Biochemical Outcomes

Not applicable.

<a id="heading-3.1.9.7"></a>

##### 3.1.9.7 Statistical Analysis Description

<a id="heading-3.1.9.7.1"></a>

###### 3.1.9.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.9.7.1-1"></a>

###### Reported participant

> “our patient”

Source: [McCormick et al. (1985)](https://pubmed.ncbi.nlm.nih.gov/4050860/)

<a id="heading-3.1.9.7.2"></a>

###### 3.1.9.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.9.8"></a>

##### 3.1.9.8 Results

<a id="heading-3.1.9.8.1"></a>

###### 3.1.9.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.9.8.2"></a>

###### 3.1.9.8.2 Baseline Characteristics

<a id="topic-3.1.9.8.2-1"></a>

###### Age at dichloroacetate administration

> “10.5 months”

Source: [McCormick et al. (1985)](https://pubmed.ncbi.nlm.nih.gov/4050860/)

<a id="heading-3.1.9.8.3"></a>

###### 3.1.9.8.3 Efficacy Results

<a id="topic-3.1.9.8.3-1"></a>

###### Acute biochemical response

> “a 56 and 62% reduction in the serum lactate and pyruvate levels, respectively”

Source: [McCormick et al. (1985)](https://pubmed.ncbi.nlm.nih.gov/4050860/)

<a id="heading-3.1.9.8.4"></a>

###### 3.1.9.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.9.8.5"></a>

###### 3.1.9.8.5 Safety Results

No evidence found.

<a id="heading-3.1.9.9"></a>

##### 3.1.9.9 Study Limitations

<a id="topic-3.1.9.9-1"></a>

###### Summary

The biochemical reductions were reported in one participant. They do not establish a comparative clinical benefit, long-term neurologic effect, or survival effect. No systematic adverse-event results are included in the retrieved evidence.

Source: [McCormick et al. (1985)](https://pubmed.ncbi.nlm.nih.gov/4050860/)

<a id="heading-3.1.10"></a>

#### 3.1.10 Oral dichloroacetate in chronic congenital lactic acidosis

<a id="heading-3.1.10.1"></a>

##### 3.1.10.1 Objective

Additional sources: [Kuroda et al. (1986)](https://pubmed.ncbi.nlm.nih.gov/3099068/)

<a id="heading-3.1.10.2"></a>

##### 3.1.10.2 Location and Study Date

No evidence found.

<a id="heading-3.1.10.3"></a>

##### 3.1.10.3 Study Design

Additional sources: [Kuroda et al. (1986)](https://pubmed.ncbi.nlm.nih.gov/3099068/)

<a id="heading-3.1.10.4"></a>

##### 3.1.10.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.10.5"></a>

##### 3.1.10.5 Treatment

<a id="topic-3.1.10.5-1"></a>

###### Dose per administration

> “50 mg per kg body weight”

Source: [Kuroda et al. (1986)](https://pubmed.ncbi.nlm.nih.gov/3099068/)

<a id="heading-3.1.10.6"></a>

##### 3.1.10.6 Study Outcomes

<a id="heading-3.1.10.6.1"></a>

###### 3.1.10.6.1 Rationale for Using Blood Lactate as a Biochemical Outcome

Not applicable.

<a id="heading-3.1.10.7"></a>

##### 3.1.10.7 Statistical Analysis Description

<a id="heading-3.1.10.7.1"></a>

###### 3.1.10.7.1 Number of Participants (Planned and Analyzed)

Additional sources: [Kuroda et al. (1986)](https://pubmed.ncbi.nlm.nih.gov/3099068/)

<a id="heading-3.1.10.7.2"></a>

###### 3.1.10.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.10.8"></a>

##### 3.1.10.8 Results

<a id="heading-3.1.10.8.1"></a>

###### 3.1.10.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.10.8.2"></a>

###### 3.1.10.8.2 Baseline Characteristics

<a id="topic-3.1.10.8.2-1"></a>

###### Reported ages

> “a newborn infant”
> “a 15-year-old boy”

Source: [Kuroda et al. (1986)](https://pubmed.ncbi.nlm.nih.gov/3099068/)

<a id="heading-3.1.10.8.3"></a>

###### 3.1.10.8.3 Efficacy Results

<a id="topic-3.1.10.8.3-1"></a>

###### Blood lactate response in the first participant

> “blood lactate level rapidly decreased”

Source: [Kuroda et al. (1986)](https://pubmed.ncbi.nlm.nih.gov/3099068/)

<a id="heading-3.1.10.8.4"></a>

###### 3.1.10.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.10.8.5"></a>

###### 3.1.10.8.5 Safety Results

<a id="topic-3.1.10.8.5-1"></a>

###### Drug accumulation in the first participant

> “DCA accumulated in the blood”

Source: [Kuroda et al. (1986)](https://pubmed.ncbi.nlm.nih.gov/3099068/)

<a id="heading-3.1.10.9"></a>

##### 3.1.10.9 Study Limitations

<a id="topic-3.1.10.9-1"></a>

###### Summary

The report describes two participants of different ages, without a randomized comparator. Reduced blood lactate in the first participant is a biochemical observation, not evidence of a general clinical treatment effect. Reported drug accumulation limits interpretation of biochemical response without considering exposure and toxicity.

Source: [Kuroda et al. (1986)](https://pubmed.ncbi.nlm.nih.gov/3099068/)

<a id="heading-3.1.11"></a>

#### 3.1.11 Neonatal pyruvate dehydrogenase deficiency with lipoate-responsive lactic acidaemia

<a id="heading-3.1.11.1"></a>

##### 3.1.11.1 Objective

Additional sources: [Byrd et al. (1989)](https://pubmed.ncbi.nlm.nih.gov/2501097/)

<a id="heading-3.1.11.2"></a>

##### 3.1.11.2 Location and Study Date

No evidence found.

<a id="heading-3.1.11.3"></a>

##### 3.1.11.3 Study Design

Additional sources: [Byrd et al. (1989)](https://pubmed.ncbi.nlm.nih.gov/2501097/)

<a id="heading-3.1.11.4"></a>

##### 3.1.11.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.11.5"></a>

##### 3.1.11.5 Treatment

<a id="topic-3.1.11.5-1"></a>

###### Acute treatment modalities

> “peritoneal dialysis, dichloroacetate therapy”

Source: [Byrd et al. (1989)](https://pubmed.ncbi.nlm.nih.gov/2501097/)

<a id="heading-3.1.11.6"></a>

##### 3.1.11.6 Study Outcomes

<a id="heading-3.1.11.6.1"></a>

###### 3.1.11.6.1 Rationale for Using Blood Lactate as a Biochemical Outcome

Not applicable.

<a id="heading-3.1.11.7"></a>

##### 3.1.11.7 Statistical Analysis Description

<a id="heading-3.1.11.7.1"></a>

###### 3.1.11.7.1 Number of Participants (Planned and Analyzed)

Additional sources: [Byrd et al. (1989)](https://pubmed.ncbi.nlm.nih.gov/2501097/)

<a id="heading-3.1.11.7.2"></a>

###### 3.1.11.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.11.8"></a>

##### 3.1.11.8 Results

<a id="heading-3.1.11.8.1"></a>

###### 3.1.11.8.1 Participant Disposition

<a id="topic-3.1.11.8.1-1"></a>

###### Survival outcome

> “She died aged 1 year 8 months”

Source: [Byrd et al. (1989)](https://pubmed.ncbi.nlm.nih.gov/2501097/)

<a id="heading-3.1.11.8.2"></a>

###### 3.1.11.8.2 Baseline Characteristics

<a id="topic-3.1.11.8.2-1"></a>

###### Age and sex at presentation

> “2-day-old girl”

Source: [Byrd et al. (1989)](https://pubmed.ncbi.nlm.nih.gov/2501097/)

<a id="heading-3.1.11.8.3"></a>

###### 3.1.11.8.3 Efficacy Results

<a id="topic-3.1.11.8.3-1"></a>

###### Lactate response attributed to lipoic acid

> “Lactate homeostasis responded to pharmacological supplements of lipoic acid.”

Source: [Byrd et al. (1989)](https://pubmed.ncbi.nlm.nih.gov/2501097/)

<a id="heading-3.1.11.8.4"></a>

###### 3.1.11.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.11.8.5"></a>

###### 3.1.11.8.5 Safety Results

No evidence found.

<a id="heading-3.1.11.9"></a>

##### 3.1.11.9 Study Limitations

<a id="topic-3.1.11.9-1"></a>

###### Summary

The participant received multiple treatment modalities, and the reported lactate response was attributed to lipoic acid rather than isolated dichloroacetate exposure. Death at 1 year 8 months and the absence of a comparator prevent interpreting biochemical improvement as a demonstrated survival benefit.

Source: [Byrd et al. (1989)](https://pubmed.ncbi.nlm.nih.gov/2501097/)

<a id="heading-3.1.12"></a>

#### 3.1.12 Transient response to dichloroacetate in an infant with pyruvate decarboxylase deficiency

<a id="heading-3.1.12.1"></a>

##### 3.1.12.1 Objective

No evidence found.

<a id="heading-3.1.12.2"></a>

##### 3.1.12.2 Location and Study Date

No evidence found.

<a id="heading-3.1.12.3"></a>

##### 3.1.12.3 Study Design

No evidence found.

<a id="heading-3.1.12.4"></a>

##### 3.1.12.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.12.5"></a>

##### 3.1.12.5 Treatment

No evidence found.

<a id="heading-3.1.12.6"></a>

##### 3.1.12.6 Study Outcomes

<a id="heading-3.1.12.6.1"></a>

###### 3.1.12.6.1 Rationale for Using Clinical and Biochemical Response as an Outcome Measure

No evidence found.

<a id="heading-3.1.12.7"></a>

##### 3.1.12.7 Statistical Analysis Description

<a id="heading-3.1.12.7.1"></a>

###### 3.1.12.7.1 Number of Participants (Planned and Analyzed)

No evidence found.

<a id="heading-3.1.12.7.2"></a>

###### 3.1.12.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.12.8"></a>

##### 3.1.12.8 Results

<a id="heading-3.1.12.8.1"></a>

###### 3.1.12.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.12.8.2"></a>

###### 3.1.12.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.12.8.3"></a>

###### 3.1.12.8.3 Efficacy Results

Additional sources: [Tóth et al. (1993)](https://pubmed.ncbi.nlm.nih.gov/8355121/)

<a id="heading-3.1.12.8.4"></a>

###### 3.1.12.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.12.8.5"></a>

###### 3.1.12.8.5 Safety Results

No evidence found.

<a id="heading-3.1.12.9"></a>

##### 3.1.12.9 Study Limitations

No evidence found.

<a id="heading-3.1.13"></a>

#### 3.1.13 Dichloroacetate as treatment for congenital lactic acidosis

<a id="heading-3.1.13.1"></a>

##### 3.1.13.1 Objective

No evidence found.

<a id="heading-3.1.13.2"></a>

##### 3.1.13.2 Location and Study Date

No evidence found.

<a id="heading-3.1.13.3"></a>

##### 3.1.13.3 Study Design

No evidence found.

<a id="heading-3.1.13.4"></a>

##### 3.1.13.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.13.5"></a>

##### 3.1.13.5 Treatment

No evidence found.

<a id="heading-3.1.13.6"></a>

##### 3.1.13.6 Study Outcomes

<a id="heading-3.1.13.6.1"></a>

###### 3.1.13.6.1 Rationale for Using Clinical and Biochemical Response as an Outcome Measure

No evidence found.

<a id="heading-3.1.13.7"></a>

##### 3.1.13.7 Statistical Analysis Description

<a id="heading-3.1.13.7.1"></a>

###### 3.1.13.7.1 Number of Participants (Planned and Analyzed)

No evidence found.

<a id="heading-3.1.13.7.2"></a>

###### 3.1.13.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.13.8"></a>

##### 3.1.13.8 Results

<a id="heading-3.1.13.8.1"></a>

###### 3.1.13.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.13.8.2"></a>

###### 3.1.13.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.13.8.3"></a>

###### 3.1.13.8.3 Efficacy Results

Additional sources: [Coude et al. (1978)](https://pubmed.ncbi.nlm.nih.gov/714110/)

<a id="heading-3.1.13.8.4"></a>

###### 3.1.13.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.13.8.5"></a>

###### 3.1.13.8.5 Safety Results

No evidence found.

<a id="heading-3.1.13.9"></a>

##### 3.1.13.9 Study Limitations

No evidence found.

<a id="heading-3.1.14"></a>

#### 3.1.14 Dichloroacetate in the treatment of congenital lactic acidosis

<a id="heading-3.1.14.1"></a>

##### 3.1.14.1 Objective

No evidence found.

<a id="heading-3.1.14.2"></a>

##### 3.1.14.2 Location and Study Date

No evidence found.

<a id="heading-3.1.14.3"></a>

##### 3.1.14.3 Study Design

No evidence found.

<a id="heading-3.1.14.4"></a>

##### 3.1.14.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.14.5"></a>

##### 3.1.14.5 Treatment

No evidence found.

<a id="heading-3.1.14.6"></a>

##### 3.1.14.6 Study Outcomes

<a id="heading-3.1.14.6.1"></a>

###### 3.1.14.6.1 Rationale for Using Clinical and Biochemical Response as an Outcome Measure

No evidence found.

<a id="heading-3.1.14.7"></a>

##### 3.1.14.7 Statistical Analysis Description

<a id="heading-3.1.14.7.1"></a>

###### 3.1.14.7.1 Number of Participants (Planned and Analyzed)

No evidence found.

<a id="heading-3.1.14.7.2"></a>

###### 3.1.14.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.14.8"></a>

##### 3.1.14.8 Results

<a id="heading-3.1.14.8.1"></a>

###### 3.1.14.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.14.8.2"></a>

###### 3.1.14.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.14.8.3"></a>

###### 3.1.14.8.3 Efficacy Results

Additional sources: [Aynsley-Green et al. (1984)](https://pubmed.ncbi.nlm.nih.gov/6429437/)

<a id="heading-3.1.14.8.4"></a>

###### 3.1.14.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.14.8.5"></a>

###### 3.1.14.8.5 Safety Results

No evidence found.

<a id="heading-3.1.14.9"></a>

##### 3.1.14.9 Study Limitations

No evidence found.

<a id="heading-3.1.15"></a>

#### 3.1.15 PHEMI

<a id="heading-3.1.15.1"></a>

##### 3.1.15.1 Objective

No evidence found.

<a id="heading-3.1.15.2"></a>

##### 3.1.15.2 Location and Study Date

No evidence found.

<a id="heading-3.1.15.3"></a>

##### 3.1.15.3 Study Design

No evidence found.

<a id="heading-3.1.15.4"></a>

##### 3.1.15.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.15.5"></a>

##### 3.1.15.5 Treatment

No evidence found.

<a id="heading-3.1.15.6"></a>

##### 3.1.15.6 Study Outcomes

<a id="heading-3.1.15.6.1"></a>

###### 3.1.15.6.1 Rationale for Using Lactate Reduction as the Primary Endpoint

No evidence found.

<a id="heading-3.1.15.7"></a>

##### 3.1.15.7 Statistical Analysis Description

<a id="heading-3.1.15.7.1"></a>

###### 3.1.15.7.1 Number of Participants (Planned and Analyzed)

No evidence found.

<a id="heading-3.1.15.7.2"></a>

###### 3.1.15.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.15.8"></a>

##### 3.1.15.8 Results

<a id="heading-3.1.15.8.1"></a>

###### 3.1.15.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.15.8.2"></a>

###### 3.1.15.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.15.8.3"></a>

###### 3.1.15.8.3 Efficacy Results

Additional sources: [Marchet et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40087083/)

<a id="heading-3.1.15.8.4"></a>

###### 3.1.15.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.15.8.5"></a>

###### 3.1.15.8.5 Safety Results

No evidence found.

<a id="heading-3.1.15.9"></a>

##### 3.1.15.9 Study Limitations

No evidence found.

<a id="heading-3.1.16"></a>

#### 3.1.16 Effect of sodium dichloroacetate on human pyruvate metabolism

<a id="heading-3.1.16.1"></a>

##### 3.1.16.1 Objective

Additional sources: [Naito et al. (1989)](https://pubmed.ncbi.nlm.nih.gov/2751069/)

<a id="heading-3.1.16.2"></a>

##### 3.1.16.2 Location and Study Date

No evidence found.

<a id="heading-3.1.16.3"></a>

##### 3.1.16.3 Study Design

<a id="topic-3.1.16.3-1"></a>

###### Single-participant observation

> “a patient”

Source: [Naito et al. (1989)](https://pubmed.ncbi.nlm.nih.gov/2751069/)

<a id="heading-3.1.16.4"></a>

##### 3.1.16.4 Eligibility Criteria

No evidence found.

<a id="heading-3.1.16.5"></a>

##### 3.1.16.5 Treatment

<a id="topic-3.1.16.5-1"></a>

###### Oral dose and administration frequency

> “12.5 to 50 mg/kg body weight twice or three times per day”

Source: [Naito et al. (1989)](https://pubmed.ncbi.nlm.nih.gov/2751069/)

<a id="heading-3.1.16.6"></a>

##### 3.1.16.6 Study Outcomes

<a id="heading-3.1.16.6.1"></a>

###### 3.1.16.6.1 Rationale for Using Lactate During Exercise as a Biochemical Outcome

No evidence found.

<a id="heading-3.1.16.7"></a>

##### 3.1.16.7 Statistical Analysis Description

<a id="heading-3.1.16.7.1"></a>

###### 3.1.16.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.16.7.1-1"></a>

###### Reported participant

> “a patient”

Source: [Naito et al. (1989)](https://pubmed.ncbi.nlm.nih.gov/2751069/)

<a id="heading-3.1.16.7.2"></a>

###### 3.1.16.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.16.8"></a>

##### 3.1.16.8 Results

<a id="heading-3.1.16.8.1"></a>

###### 3.1.16.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.16.8.2"></a>

###### 3.1.16.8.2 Baseline Characteristics

<a id="topic-3.1.16.8.2-1"></a>

###### Underlying mitochondrial disorder

> “mitochondrial encephalomyopathy associated with congenital lactic acidemia”

Source: [Naito et al. (1989)](https://pubmed.ncbi.nlm.nih.gov/2751069/)

<a id="heading-3.1.16.8.3"></a>

###### 3.1.16.8.3 Efficacy Results

<a id="topic-3.1.16.8.3-1"></a>

###### Exercise-associated lactate response

> “increases in the lactate levels in the blood and urine during exercise were markedly reduced.”

Source: [Naito et al. (1989)](https://pubmed.ncbi.nlm.nih.gov/2751069/)

<a id="heading-3.1.16.8.4"></a>

###### 3.1.16.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.16.8.5"></a>

###### 3.1.16.8.5 Safety Results

No evidence found.

<a id="heading-3.1.16.9"></a>

##### 3.1.16.9 Study Limitations

<a id="topic-3.1.16.9-1"></a>

###### Summary

This is a single-participant pharmacologic observation in mitochondrial encephalomyopathy with congenital lactic acidemia. The report does not provide a randomized comparison or establish that the participant had the target PDCD diagnosis. The exercise-related biochemical response therefore provides indirect evidence rather than an estimate of SL1009 clinical efficacy in PDCD.

Source: [Naito et al. (1989)](https://pubmed.ncbi.nlm.nih.gov/2751069/)

## Related pages
- [SL1009 (sodium dichloroacetate): Pyruvate dehydrogenase complex deficiency](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Terms and abbreviations](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/terms-and-abbreviations.md)
- [SL1009 (sodium dichloroacetate): Pyruvate dehydrogenase complex deficiency](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/executive-summary) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/executive-summary.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Product information and disease description](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/product-information-and-disease-description.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Economic information and modeling report](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/economics) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/economics.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: References](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/references) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/references.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: prevalence by geography](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/prevalence) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/prevalence.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/cost-effectiveness-analyses.md)
